Funding for this research was provided by:
GSK Consumer Healthcare Company (N/A)
Received: 23 May 2019
Accepted: 27 September 2019
First Online: 31 October 2019
Ethics approval and consent to participate
: The protocol was reviewed and approved by an independent ethics committee (South East Wales Local Research Ethics Committees Panel D, Cardiff, UK; reference number: 11/WA/0286), and the study was conducted in accordance with requirements specified in the Declaration of Helsinki. All subjects provided informed consent prior to participation in this noninterventional study.
: RE regularly acts as a consultant to the pharmaceutical industry, including work for GlaxoSmithKline. PM is an employee of GlaxoSmithKline Consumer Healthcare Company, Nyon, Switzerland.